Advance of theragnosis biomarkers in lung cancer: from clinical to molecular pathology and biology.

Advance of theragnosis biomarkers in lung cancer: from clinical to molecular pathology and biology.

J Thorac Dis. 2019 Jan;11(Suppl 1):S3-S8

Authors: Alidousty C, Baar T, Heydt C, Wagener-Ryczek S, Kron A, Wolf J, Buettner R, Schultheis AM

Abstract
One distinct molecular subtype of non-small cell lung cancer (NSCLC) is defined by rearrangement of the anaplastic lymphoma kinase (ALK). The increasing knowledge over the last years has enabled the continuous improvement of ALK inhibitors; however, resistance in these patients remains a major concern. In this review, we summarize recent findings in ALK+-adenocarcinoma of the lung, highlighting the role of TP53 mutations in this specific cancer type and suggest new diagnostic strategies for the future, in order to improve patient's outcome.

PMID: 30775023 [PubMed]

from A via a.sfakia on Inoreader http://bit.ly/2GBfDM6